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visiting psychiatrists. The issues of over-medication and polypsy-
chopharmacy deserve further attention.
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OBJECTIVES: Up to 75% of patients with bipolar disorder
report at least one lifetime hospitalization; patients treated with
second generation antipsychotics (SGAs) and mood stabilizers
(MS) are hospitalized more frequently than those treated with
MS monotherapy. It is not clear whether different SGAs differ-
entially reduce the risk of hospitalization in this at-risk popu-
lation, therefore the purpose of this study is to characterize
hospitalization rates in patients treated with adjunctive
SGA-MS combination therapy. METHODS: A retrospective
propensity score-matched cohort study was conducted in the
LabRx integrated claims database from January 2003 through
December 2006. Patients 18–65 with bipolar disorder and 180
days of pre-index enrollment without SGA therapy and 90 days
post-index enrollment were eligible for inclusion. MS therapy
was initiated within 30 days prior to or following index SGA
prescription. Multivariate logistic regression was used to esti-
mate the risk of hospitalization in patients treated with arip-
iprazole, olanzapine, quetiapine, risperidone, or ziprasidone
during the 90 day follow-up period. RESULTS: Of 7134
patients meeting inclusion criteria, 920 patients on aripiprazole
were matched to 920 on olanzapine, quetiapine, or risperidone,
while 518 aripiprazole patients were matched to 518 on
ziprasidone. Hospitalization rates in the ﬁrst 90 days following
index prescription was 9.3% (range 7.1–12.8%). Compared to
aripiprazole, patients on adjunctive SGAs demonstrated statis-
tically signiﬁcantly greater risks of hospitalization (olanzapine
OR 1.8, 95%CI 1.3, 2.7; quetiapine OR 1.5, 95%CI 1.1, 2.2;
risperidone OR 1.8, 95%CI 1.3, 2.6; ziprasidone OR 1.7,
95%CI 1.1, 2.7). CONCLUSIONS: Hospitalization in the ﬁrst
90 days following initiation of combination mood stabilizer-
SGA therapy is relatively common and inﬂuenced by choice of
SGA. This difference may be due to dosing and titration under
real world conditions.
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OBJECTIVES: Empirical studies show a severe undertreatment
of patients with Alzheimer’s disease in Germany. This compara-
tive online panel survey investigates potential causes for under-
treatment among general practitioners (GPs) and neurologists/
psychiatrists. METHODS: A total of 100 neurologists/
psychiatrists and 302 GPs were included in an online panel
survey. Participating GPs had experiences in treating diabetes,
asthma, depression, epilepsy, migraine and dementia; neurolo-
gists were experienced in schizophrenia, depression, epilepsy,
multiple sclerosis, migraine and dementia. Participants were
asked to compare these therapeutic areas in 8 items: urgency of
treatment, therapeutic options, difﬁculties in diagnosis, knowl-
edge on guidelines, difﬁculties in patient and care-giver commu-
nication, inﬂuence of budget restrictions, experiences in
switching therapy and referrals to specialists. A Likert-rating
scale (1–5) was used for assessing. An additional open question
addressed reasons for discontinuing therapy with antidementive
drugs. RESULTS: For Alzheimer’s disease GPs see lowest
urgency for treatment (2.2; 1.3 in diabetes), lowest number of
therapeutic options (3.5; 1.5 in asthma), largest difﬁculties in
diagnosis (3.3; 1.7 in diabetes), largest difﬁculties in patient and
care-giver communication (3.7; 1.9 in diabetes) and highest
budget restrictions (2.0; 2.8 in epilepsy). GPs’ knowledge of
guidelines is lowest in epilepsy (3.4) and dementia (3.0; 1.7 in
diabetes); their experience in therapeutic switches is lowest, the
number of referrals to specialists highest. Neurologists agree
with GPs that therapeutic options in dementia are lowest (3.5,
1.5 in schizophrenia) and budget pressure is highest (1.9; 2.7 in
epilepsy). They see a higher urgency of treatment for Alzheimer
and show more experience in treatment. Both groups agreed
that budget restraints are the most important reason for discon-
tinuing treatment with antidementive drugs. CONCLUSIONS:
Results suggest that budget constraints for GPs and
neurologists/psychiatrists are the dominant reason for under-
treatment of patients with Alzheimer’s disease. To ensure
evidence-based treatment with antidementive drugs in Germany
budget constraints need to be reduced.
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OBJECTIVES: Controlling pharmaceutical expenditures is of
particular interest to governments, as pharmaceuticals present
one of the main components of health care expenditures. Patent
expiries of drugs are important, as dispensing (cheaper) generic
drugs potentially results in lower pharmaceutical expenditures.
Therefore, modelling generic substitution patterns is highly rel-
evant as this can provide useful cost-cutting decision support.
The aim of this study was to model the duration until patients
switch from branded to generic drugs, in relation to various
inﬂuencing variables METHODS: Data were obtained from
Dutch pharmacy dispensing records from IADB.nl. We focused
on antidepressant prescription data. To identify a pattern on the
underlying diffusion process, the analysis was applied to four
antidepressants whose patent recently expired (ﬂuoxetine, par-
oxetine, citalopram, sertraline). Duration analysis techniques
were used to estimate the probability of patients to switch to a
generic drug over time, and to estimate the effect of different
covariates (e.g. patient, pharmacist and general practitioner char-
acteristics) on this switching probability. Since interval censored
data were used, discrete duration methods were applied which
resulted in the estimation of a binary regression model.
RESULTS: A higher probability for patients to switch from a
branded to a generic drug within the ﬁrst ﬁve months after patent
expiry was identiﬁed. Switching probabilities were mainly
affected by the general practitioners’ and pharmacists’ inclination
to provide generic drugs, the age, the experience of the patient on
the speciﬁc drug and the amount of different generic drugs intro-
duced in the market. CONCLUSIONS: Despite differences in
pharmacy dispensing patterns for different antidepressants
studied, we generally found common patterns in generic substi-
tution. Next to the inclination of health care professionals,
patient characteristics, time and the amount of available generic
alternatives affect generic substitution signiﬁcantly. However,
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future research in drug classes other than antidepressants should
be conducted to verify our ﬁndings.
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OBJECTIVES: Because prescribing in routine clinical practice
reﬂects both the physicians’ perception of the efﬁcacy and safety
of a drug and the patient’s characteristics, this study aimed at
comparing the real-life proﬁle of patients prescribed escitalo-
pram, SSRIs or venlafaxine in primary care in order to better
understand drugs-related determinants of prescription.
METHODS: This retrospective study used data from the General
Practitioners Research Database and included adult patients with
an incident prescription (no antidepressant in the previous12-
month) of escitalopram, an SSRI or venlafaxine between January
1, 2003 and June 30, 2005, and an associated diagnosis of
depression. Demographics, disease and treatment characteristics,
and health care resource consumption were assessed in the
12-month before the new prescription and compared across
treatment groups. RESULTS: A total of 6,910 patients were
prescribed escitalopram, 47,853 SSRIs and 2,832 venlafaxine.
Compared with SSRIs-treated patients, escitalopram-treated
patients were younger (p = 0.001), more often diagnosed with
severe depression (p = 0.018), and more often suffering from
associated anxiety (p < 0.001). They also had more hospitalisa-
tions (p = 0.021), referrals (p = 0.020), anxiolytics (p < 0.001)
and hypnotics (p < 0.001) prescriptions at baseline. Compared
with venlafaxine-treated patients, escitalopram-treated patients
were younger (p < 0.001), less often diagnosed with severe
depression (p < 0.001) and concomitant anxiety (p < 0.001), and
had lighter psychiatric history (p = 0.002). However, they were
more often suffering from cardio-respiratory diseases (p = 0.02).
Baseline resource use was sensibly similar between treatment
groups. CONCLUSIONS: Important differences in patients’ pro-
ﬁles were observed between escitalopram, generic SSRIs and
venlafaxine, and correspond to current data on the drugs’ efﬁ-
cacy and safety proﬁle: physicians prescribed escitalopram and
venlafaxine to patients with more severe depression. The subse-
quent choice between escitalopram and venlafaxine was based on
safety proﬁles, escitalopram being perceived as safer and being
prescribed to patients with a heavier somatic background. These
differences have to be adjusted for in further real-life drug effec-
tiveness studies otherwise they can importantly bias the results.
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OBJECTIVES: Awareness of adult ADHD is low. Even though
guidelines have existed in Germany since 2003, diagnosis and
treatment are not standardized and remain difﬁcult in practice,
often complicated by comorbidities. This analysis investigates
prevalent psychiatric comorbidities and the applied pharmaco-
therapy of adult patients with ADHD diagnosed by general prac-
titioners (GPs) or by neurologists/psychiatrics (NPs) in Germany
in 2007. METHODS: A retrospective database analysis of adult
patients aged 19–59 diagnosed with ADHD (ICD-10 code F90)
was performed, using the IMS Disease Analyzer that contains
electronic medical records of representative panels of German
GPs and NPs, capturing drug prescription and diagnoses.
RESULTS: Patients were identiﬁed through the records of NPs
seeing 122,666 patients and GPs seeing 1.16 million patients,
aged 19–59. NPs diagnosed ADHD in 851 adults (annual preva-
lence 0.69%, 60% male), of which 521 had at least one psychi-
atric co-diagnosis (33% mood disorders F30-39, 19% neurotic,
stress-related and somatoform disorders F40-48). In 214 of 493
GPs’ ADHD patients (annual prevalence 0.04%, 61% male), at
least one psychiatric disorder was co-diagnosed (18% F30-39,
19% F40-48). A total of 48.8% of the NPs’ patients (27.2% of
the GPs’) without a psychiatric comorbidity were treated with
Methylphenidate (MPH) and 5.8% (0.4%) with MPH plus at
least one antidepressant prescription. Treatment differed in
patients with psychiatric comorbidities of which 22.1% (14.0%)
received MPH, but 18.6% (9.8%) MPH plus at least one anti-
depressant. NPs treated other 186 (GPs 142) patients without
diagnosed ADHD (F90) with MPH. CONCLUSIONS: Adminis-
trative prevalence of adult ADHD was low compared to data
derived from literature and both prevalence and comorbidity
proﬁle differed in age, gender and specialist. The pharmaco-
therapy of GPs and NPs depended on prevalent comorbidities
but did not show consistency according to guidelines. A further
understanding of adult ADHD and its treatment opportunities is
needed.
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OBJECTIVES: To describe the frequency of physical injuries and
compare the costs of care from a United States (US) payer per-
spective before and after emergent epilepsy care. METHODS:
This retrospective claims database analysis utilized the PHAR-
Metrics database from 90 regional US health plans. Patients
received care between July 1, 2005 and June 30, 2006 in an
ambulance, emergency room, or inpatient hospital with an
Episode Treatment Grouper of epilepsy without surgery. The
index date was the earliest date of emergent epilepsy care with a
study period of 6 months pre and post-index. Eligible patients
had at least one diagnosis for epilepsy (ICD-9-CM 345.xx,
excluding 345.6) were 12–64 years of age, received 145 days
supply of antiepileptic drugs without emergent care for epilepsy
in the pre-index period, and had continuous eligibility for 6
months pre-index and post-index. Injuries coded on the index
date were described according to ICD-9-CM groupings. Total
epilepsy-related, and non-epilepsy-related direct medical costs
paid to the provider were compared before and after index date
using non-parametric tests for paired samples. Injury-related
costs were also described. RESULTS: A total of 9.4% (n = 146)
of the 1213 patients receiving emergent care for a seizure event
experienced a co-occurring injury on the same date. The majority
of injuries were comprised of superﬁcial injuries and contusions
(28%), fractures (21%), open wounds or injury to blood vessels
(19%) intracranial injury (10%), and/or medication toxicity
(10%). Both per patient non-epilepsy-related (mean =
$3997.23US) and epilepsy-related (mean = US$992.30) direct
medical costs of care pre-index were signiﬁcantly different
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